CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 180 enrolled
Drug / intervention
Immunosuppressive Agentsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02294032
NCT02294032N/ACompleted
CompareCT.gov

The Role of B Cells in Kidney Allograft Dysfunction

Loma Linda University·observational·Posted Nov 19, 2014·Updated May 19, 2023

In Brief

An observational study evaluating Immunosuppressive Agents for Kidney; Complications, Allograft and Transplantation Infection. Completed, enrolled 180 participants across 1 site.

Detailed Summary

The purpose of this study is to understand the role of specific B cells in activating or repressing an anti-allograft immune response after kidney transplantation. In this study, blood will be collected from kidney transplant patients during different timepoints, prior to and after their transplant. Knowledge gained from study findings will be used to develop therapeutic strategies to prevent antibody-mediated rejection, which is a major cause of long-term graft loss in kidney transplant patients.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsKidney; Complications, Allograft, Transplantation Infection
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 19, 2014
Enrollment StartAug 28, 2014
Primary CompletionApr 24, 2023
TodayJul 2, 2026
Enrollment to primary: 8.7 yearsPosted 11.6 years ago

Interventions

Immunosuppressive Agentsdrug

standard of care for patients post-transplant